In 1998, I embarked on my pre-doctoral studies in the laboratory of Prof. Klaus Aktories at the Institute of Experimental and Clinical Pharmacology and Toxicology, located at the University of Freiburg in Germany. During this time, my research focused on signal transduction pathways, specifically on elucidating the functions and roles of small GTPase proteins from the Rho family in allergic responses.
In 2001, I pursued my postdoctoral studies under the guidance of Prof. Wilhelm Krek. Initially, I joined the Novartis Friedrich Miescher Institute (FMI), and subsequently, I continued my research at the Institute of Cell Biology at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland.
During my postdoctoral studies, I focused on studying the signaling pathways associated to the growth factor and nutrient cascades. In January 2010, I established an independent research group specializing in the field of nutrients and cancer at CNIO.
Head of the Growth Factor, Nutrients and Cancer Group Spanish National Cancer Research Centre (CNIO)
NABIL DJOUDER
Throughout my tenure, I developed expertise in generating and utilizing genetically engineered mouse models, including the creation of two conditional knock-out and five conditional knock-in mouse models.
My research efforts were centered on identifying the molecular mechanisms that link environmental stresses to the pathogenesis of diseases affecting the digestive system organs. Early on, I proposed the concept that metabolic dysfunctions drive genomic instability, highlighting that the hallmarks of cancer are intrinsic to different time-dependent events occurring during tumorigenesis.
Additionally, I played a crucial role in determining the significance of NAD+ depletion in DNA damage and cancer development. Furthermore, I pioneered the use of nicotinamide riboside as an NAD+ supplement for the prevention and treatment of cancer. My contributions have been recognized through several distinctions, including the prestigious Ramon y Cajal Award, as well as national and international funding. These accomplishments led to my promotion to the position of Senior Group Leader in January 2018.
Overall, my research achievements and advancements in the field of nutrients and cancer have received acknowledgment and rewards, further solidifying my expertise in this area.
